Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Asahi Kasei Licenses AK138 Series of Compounds to Altheos
April 12, 2010
- JGA to Suspend Taiyo's Membership for 1 Year
April 12, 2010
- District Court Rules in Favor of Prohibition of Online Sale of Classes 1, 2 OTC Drugs
April 12, 2010
- ASKA Licenses Rifaximin from Alfa Wassermann
April 12, 2010
- President Aratani to Step Down at Taiyo
April 12, 2010
- 83rd Annual Meeting of the Japanese Pharmacological Society
April 12, 2010
- Takeda to Comarket Galantamine with Janssen
April 12, 2010
- FFP Starts Marketing 178 Products with 30 MRs
April 12, 2010
- US Law to Require Companies to Disclose Payments to Physicians
April 12, 2010
- Tokyo District Court Rejects Teva's Lawsuit against Kyowa Kirin
April 12, 2010
- Denosumab Prevents SRE in Breast Cancer
April 12, 2010
- Toyama Pref. to Organize 4 Tours of Generic Makers for Healthcare Providers in FY2010
April 12, 2010
- Average of 10.1 Medical Doctors Employed by Pharm. Companies in Japan: JAPhMed
April 12, 2010
- 10 APIs Including Vildagliptin Added to NHI Price List
April 12, 2010
- Domestic Production of Drugs Up 2.6% to ¥6,620 Bil. in FY2008
April 12, 2010
- 80% Rule Applied to Exforge, Rezaltas
April 12, 2010
- The Eyes Have It －the Value of Mejikara
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
April 12, 2010
- Victoza's NHI Pricing Withheld
April 12, 2010
- Dr Haranaka Elected as New JMA President
April 12, 2010
- Chuikyo to Reconsider 14-Day Limit to Prescriptions
April 12, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…